David Andrews

Dr. David Andrews

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
David DrewryDavid Drewry
David Drewry
CWCarrow Wells
Carrow Wells
DADavid Andrews
David Andrews
RARichard Angell
Richard Angell
HAHassan Al-Ali
Hassan Al-Ali
TWTimothy M Willson
Timothy M Willson
Protein kinases are highly tractable targets for drug discovery. However, the biological function and therapeutic potential of the majority of the 500+ human protein kinases remains unknown. We have developed physical and virtual collections of small molecule inhibitors, which we call chemogenomic sets, that are designed to inhibit the catalytic function of almost half the human protein kinases. In this manuscript we share our progress towards generation of a comprehensive kinase chemogenomic set (KCGS), release kinome profiling data of a large inhibitor set (Published Kinase Inhibitor Set 2 (PKIS2)), and outline a process through which the community can openly collaborate to create a KCGS that probes the full complement of human protein kinases.

7 October 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CSChris De Savi
Chris De Savi
RBRobert H. Bradbury
Robert H. Bradbury
ARAlfred A. Rabow
Alfred A. Rabow
RNRichard A. Norman
Richard A. Norman
CACamila de Almeida
Camila de Almeida
ZWZena Wilson
Zena Wilson

Verified
Journal Article
Open access
PDF file
CWCarrow Wells
Carrow Wells
HAHassan Al-Ali
Hassan Al-Ali
DADavid Andrews
David Andrews
CAChristopher R. M. Asquith
Christopher R. M. Asquith
Alison Donnelly AxtmanAlison Donnelly Axtman
Alison Donnelly Axtman
David DrewryDavid Drewry
David Drewry
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.

2 February 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMartin J. Slater
Martin J. Slater
EAElizabeth M. Amphlett
Elizabeth M. Amphlett
DADavid Andrews
David Andrews
GBGianpaolo Bravi
Gianpaolo Bravi
GBGeorge Burton
George Burton
AWAlan Wonacott
Alan Wonacott

1 November 1991 in International Journal of Peptide and Protein Research
Verified
Journal Article
Closed access
PDF file
DADavid Andrews
David Andrews
JKJ. Kitchin
J. Kitchin
PSP. W. Seale
P. W. Seale

9 January 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NINiall Igoe
Niall Igoe
EBElliott D. Bayle
Elliott D. Bayle
OFOleg Fedorov
Oleg Fedorov
CTCynthia Tallant
Cynthia Tallant
PSPavel Savitsky
Pavel Savitsky
PFPaul V. Fish
Paul V. Fish